Suppr超能文献

临床强度调制质子治疗霍奇金淋巴瘤:哪些患者获益最大?

Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?

机构信息

Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Proton Therapy Center Czech s.r.o., Prague, Czech Republic.

出版信息

Pract Radiat Oncol. 2019 May;9(3):179-187. doi: 10.1016/j.prro.2019.01.006. Epub 2019 Jan 29.

Abstract

PURPOSE

Radiation therapy (RT) improves control of Hodgkin lymphoma (HL), but patients who undergo RT are at risk for late effects, including cardiovascular disease and second cancers, because of radiation doses to organs at risk (OARs). Proton therapy (PT) can reduce OAR doses compared with conventional photon RT. However, access to PT is currently limited, so referrals must be appropriately selective. We aimed to identify subgroups of patients with HL who could benefit the most dosimetrically from RT with PT based on the prechemotherapy disease characteristics.

METHODS AND MATERIALS

Normal tissue radiation doses were calculated for 21 patients with HL who were treated with deep-inspiration breath-hold pencil-beam scanning (PBS) PT and compared with doses from 3-dimensional conformal (3D-CRT) and partial arc volumetric modulated (PartArc) photon RT. Prechemotherapy disease characteristics associated with significant dosimetric benefits from PBS compared with photon RT were identified.

RESULTS

Treatment with PBS was well tolerated and provided with good local control. PBS provided dosimetric advantages for patients whose clinical treatment volume extended below the seventh thoracic level and for female patients with axillary disease. In addition, an increasing dosimetric benefit for some OARs was observed for increasing target volume. PBS significantly reduced the mean dose to the heart, breast, lungs, spinal cord, and esophagus. Dose homogeneity and conformity within the target volume were also superior with PBS, but some high-dose measures and hot spots were increased with PBS compared with partial arc volumetric modulated photon RT.

CONCLUSIONS

PBS gives good target coverage and local control while providing reductions in radiation dose to OARs for individuals who receive RT for HL compared with advanced photon RT. Our findings highlight groups of patients who would be expected to gain more dosimetric benefit from PBS. These findings facilitate the selection of patients who should be considered a priority for PT.

摘要

目的

放射治疗(RT)可提高霍奇金淋巴瘤(HL)的控制率,但由于危及器官(OAR)的放射剂量,接受 RT 的患者存在发生晚期效应(包括心血管疾病和第二癌症)的风险。与常规光子 RT 相比,质子治疗(PT)可降低 OAR 剂量。然而,目前获得 PT 的机会有限,因此转诊必须有适当的选择性。我们旨在根据化疗前疾病特征,确定 HL 患者亚组,这些患者从 PT 进行的 RT 中在剂量学上获益最大。

方法和材料

对 21 例接受深吸气屏气铅笔束扫描(PBS)PT 治疗的 HL 患者进行了正常组织放射剂量计算,并与 3 维适形(3D-CRT)和部分弧形容积调制(PartArc)光子 RT 的剂量进行了比较。确定了与 PBS 相比光子 RT 具有显著剂量学优势的化疗前疾病特征。

结果

PBS 治疗耐受性良好,局部控制良好。对于临床治疗体积延伸至第七胸椎以下的患者和腋窝有疾病的女性患者,PBS 提供了剂量学优势。此外,随着靶体积的增加,一些 OAR 的剂量学优势也越来越大。PBS 显著降低了心脏、乳房、肺、脊髓和食管的平均剂量。靶区内的剂量均匀性和适形性也优于 PBS,但与部分弧形容积调制光子 RT 相比,PBS 增加了某些高剂量测量值和热点。

结论

与先进的光子 RT 相比,PBS 为接受 HL RT 的个体提供了良好的靶区覆盖和局部控制,同时降低了 OAR 的放射剂量。我们的研究结果突出了预期从 PBS 获得更多剂量学获益的患者群体。这些发现有助于选择应优先考虑 PT 的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2bf/6493042/5786bd3740ac/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验